Help me with this
| Danger Sign | What it Suggests |
|---|---|
| Not feeding well / refusal to feed | Sepsis, illness |
| High fever (>38°C) or hypothermia | Infection |
| Fast breathing / chest in-drawing | Pneumonia |
| Convulsions / fits | Meningitis, hypoglycemia |
| Unconscious or difficult to wake | Severe illness |
| Yellow eyes/skin (jaundice) | Neonatal jaundice |
| Sunken fontanelle, no urine for 6+ hrs | Dehydration |
| Umbilical redness, discharge, smell | Omphalitis |
| Age | Vaccine |
|---|---|
| At birth | BCG, OPV-0, Hepatitis B (birth dose) |
| 6 weeks | DPT-1, OPV-1, Hepatitis B-2, Hib-1, Rotavirus-1, PCV-1, IPV-1 |
| 10 weeks | DPT-2, OPV-2, Hib-2, Rotavirus-2, PCV-2 |
| 14 weeks | DPT-3, OPV-3, Hib-3, Rotavirus-3, PCV-3, IPV-2 |
| 9 months | Measles/MR vaccine, Vitamin A |
Key Examiner Tips: In the OSPE, each step typically carries 0.5 marks. Speak clearly, maintain a logical sequence, demonstrate the latch/position if asked, and always close with follow-up advice. - Textbook of Family Medicine 9e, p. 539
Help me with this
| Phase | Duration | Drugs |
|---|---|---|
| Intensive Phase (IP) | 2 months (56 doses) | H (Isoniazid) + R (Rifampicin) + Z (Pyrazinamide) + E (Ethambutol) - 4 FDC daily |
| Continuation Phase (CP) | 4 months (112 doses) | H + R + E - 3 FDC daily |
| Drug | Common Side Effect |
|---|---|
| Isoniazid (H) | Tingling/numbness in hands & feet (peripheral neuropathy), liver damage |
| Rifampicin (R) | Orange/red discoloration of urine, sweat, tears - normal, not to be alarmed |
| Pyrazinamide (Z) | Joint pain, nausea, liver toxicity |
| Ethambutol (E) | Visual disturbances - blurred vision, color blindness (report immediately) |
Key Examiner Tips: Speak in sequence, maintain empathy and confidentiality throughout, explain the orange urine from Rifampicin proactively (very commonly asked), stress the importance of completing treatment to avoid MDR-TB, and always close with the Nikshay Poshan Yojana as it shows awareness of the national programme. - Park's Textbook of Preventive and Social Medicine, p. 222-233